Magee Women's Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
NCT Number: NCT05726318
To evaluate the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection symptoms in older women and the adherence to study procedures.
Looking for future studies?
Notify Me65 year and older
Female
Interventional
Phase 4
Pittsburgh, Pennsylvania, 15213, United States
To evaluate A) the feasibility of recruiting eligible subjects into a randomized trial of a culture-directed versus empiric antibiotic strategy for patient-reported urinary tract infection (UTI) symptoms in older women and B) the adherence to study procedures. We will recruit and enroll women with a history of recurrent UTI (rUTI) from the Women's Center for Bladder and Pelvic Health and the University of Pittsburgh's Clinical and Translational Science Institute (CTSI) Pitt+Me® Research Registry. Once enrolled and randomized, women will be followed for a total of 28 days to document both clinical resolution at day 7 from symptom onset and adverse events. H1) Enrolling a total of 70 subjects in <1 year (at least 10% of eligible patients) will demonstrate feasibility of recruitment and H2) Documenting at least 70% patient compliance with study procedures will confirm patient adherence to study protocol. Exploratory Aim: To explore the safety of a culture-directed UTI treatment strategy and preliminary secondary outcomes of assigned treatments. H1) There will be an overall low number of adverse events and H2) Preliminary outcome data will help power future trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
Time frame: Through study completion, an average of 17.5 months
Number and proportion of eligible subjects that were enrolled in the study
Time frame: Through study completion, an average of 17.5 months
Overall number of persons that were screened for participation
Time frame: 30 days
Number of person screened who met include/exclusion criteria divided by number participants screened
Time frame: 30 days
Number of person screened who declined or were ineligible divided by number participants screened
Time frame: 30 days
Number of persons enrolled who completed the study (at least one follow-up questionnaire and completed the day 28 questionnaire) divided by number participants enrolled
Time frame: Through study completion, an average of 17.5 months
number of participants that were enrolled each month
Time frame: 30 days
Number of persons enrolled who completed all study procedures (completed all 4 follow-up questionnaires) divided by number participants enrolled
Time frame: 30 days
Number of persons enrolled who took alternative agents for management of symptoms divided by number participants enrolled
Time frame: 30 days
Number of participants in the culture-directed arm that acquired off-protocol antibiotics for their symptoms divided by the number of participants in the culture-directed arm
Time frame: 30 days
Number of persons enrolled who completed all electronic surveys divided by number participants enrolled
Time frame: 14 days
Score of <1 on question 1 (urinary burning),3 (urinary urgency) and 5 (urinary frequency) on Urinary Tract Infection Symptom Assessment at day 14. A lower scale correlates with better symptoms with 0 being no symptoms and 1 being "little" symptoms.
Megan Bradley
Other
A Randomized Pilot and Feasibility Study of a cultuRE-Directed Approach to Urinary traCT Infection Symptoms in Older womeN: a Mixed Methods Evaluation - the REDUCTION Trial
Acronym: REDUCTION
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02944825
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
San Diego, California, United States
View Trial DetailsNCT04841226
Biofilm Formation, UTI
Tucson, Arizona, United States
View Trial DetailsNCT05408533
UTI
Cincinnati, Ohio, United States
View Trial DetailsNCT05646069
Calculi, Female Urogenital Diseases
Chicago, Illinois, United States
View Trial Details